Renhe Pharmaceutical: Indicative announcement on changes in the equity structure of the controlling shareholder and changes in the actual controller
Securities code: 000650 Securities abbreviation: Renhe Pharmaceutical Announcement number: 2026-026
Renhe Pharmaceutical Co., Ltd.
Indicative announcement on changes in the equity structure of the controlling shareholder and changes in the actual controller
The information provided by Yang Wenlong and Yang Xiao to the company is true, accurate and complete, and there are no false records, misleading statements or major omissions.
The company and all members of the board of directors guarantee that the content of the announcement is consistent with the information provided by the information disclosure obligor.
Important content reminder:
On June 10, 2026, Mr. Yang Wenlong and Mr. Yang Xiao signed the "Equity Transfer Agreement". According to the agreement, Mr. Yang Wenlong transferred 73.1137% of the equity he held in Renhe (Group) Development Co., Ltd. to his son, Mr. Yang Xiao. After the transfer is completed, Mr. Yang Wenlong no longer holds the equity of Renhe Group, and Mr. Yang Xiao holds 73.1137% of the equity of Renhe Group.
As of the date of this announcement, the company’s controlling shareholder Renhe Group holds 23.24% of the company’s shares. This equity change is a change in the equity structure of the controlling shareholder Renhe Group. It does not involve changes in the company’s shares held by Renhe Group, does not involve a tender offer, and will not result in a change in the company’s controlling shareholder. The company’s controlling shareholder is still Renhe Group.
After the completion of this equity change, Mr. Yang Xiao will become the controlling shareholder of Renhe Group and will indirectly control 23.24% of the shares of the listed company through the Renhe Group controlled by him. The actual controller of the company will be changed from Mr. Yang Wenlong to Mr. Yang Xiao.
1. Basic situation of this equity change
(1) Overview of this equity change
Recently, Renhe Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "listed company") received the "Notification Letter Regarding Changes in Equity Structure" from the controlling shareholder Renhe (Group) Development Co., Ltd. (hereinafter referred to as "Renhe Group") and learned that Mr. Yang Wenlong and Mr. Yang Xiao signed the "Equity Transfer Agreement" on June 10, 2026. According to the agreement, Mr. Yang Wenlong currently holds 73.1137% of the equity of Renhe Group. Mr. Yang Wenlong transferred 73.1137% of the equity of Renhe Group to Mr. Yang Xiao at a price of RMB 0 (hereinafter referred to as the "change in equity"). After the transfer is completed, Mr. Yang Wenlong no longer holds the equity of Renhe Group, and Mr. Yang Xiao holds 73.1137% of the equity of Renhe Group. On June 10, 2026, Renhe Group made a shareholders' meeting resolution agreeing to the above-mentioned equity transfer. Other shareholders of Renhe Group issued a "Notice of Waiver of Preemptive Right".
Yang Wenlong and Yang Xiao have a father-son relationship. Mr. Yang Xiao has served as the chairman of the company since March 2022 and is fully responsible for the company's operation and management. On June 10, 2026, Mr. Yang Wenlong transferred 73.1137% of his equity and all corresponding interests in the company's controlling shareholder Renhe Group to Mr. Yang Xiao through an agreement. This equity change meets the company's future development needs. As of now, Renhe Group holds 23.24% of the company's shares and is the controlling shareholder of the listed company. This change in equity is a change in the equity structure of Renhe Group and does not involve a tender offer obligation. It does not involve changes in the shares of the listed company held by Renhe Group and will not result in a change in the controlling shareholder of the listed company. After the completion of this transfer, the controlling shareholder of the listed company will still be Renhe Group, and the actual controller will be changed from Yang Wenlong to Yang Xiao.
After this equity change, Renhe Group still needs to complete the industrial and commercial change registration procedures.
(2) Basic information of both parties to the transfer
The resume of the transferor, Mr. Yang Wenlong, is as follows:
Mr. Yang Wenlong, born in February 1962, Han nationality, from Fengcheng, Jiangxi Province, holds a doctorate degree, is a Chinese pharmacist and senior economist. National model worker, member of the National Committee of the Chinese People's Political Consultative Conference (11th, 12th, and 13th sessions), member of the Standing Committee of the Jiangxi Provincial Committee of the Chinese People's Political Consultative Conference (13th session), member of the Central Committee of China Democratic National Construction Association (9th, 10th, and 11th session), part-time vice president of Jiangxi Federation of Industry and Commerce (General Chamber of Commerce), and chairman of Renhe Group. He has successively won the "China Charity Award", "National Model Worker", "Excellent Builder of Socialism with Chinese Characteristics", "Excellent Builder of Socialism with Chinese Characteristics in Jiangxi Province", "Top Ten Entrepreneurial Pioneers in Jiangxi Province", "Excellent Private Technology Entrepreneurs in China", "Outstanding Private Entrepreneurs in Jiangxi Province", "Top Ten Outstanding Young Entrepreneurial Stars in the First Session of Jiangxi Province", "Top Ten Sons of Jinggang in the Second Session of Jiangxi Province", "Reform and Opening 30" Honorary titles such as "Top Ten Outstanding Constructors of Jiangxi Province" and "Top Ten Caring Members of the Third Jiangxi CPPCC".
The resume of the transferee, Mr. Yang Xiao, is as follows:
Mr. Yang Xiao: Born in October 1990, Chinese nationality, no permanent residence abroad, bachelor’s degree. He once served as a postdoctoral workstation manager at the Institute of Philosophy, Chinese Academy of Social Sciences. From May 2018 to the present, he has been a director of Renhe Pharmaceutical, and from March 2022 to the present, he has been the chairman of Renhe Pharmaceutical; from May 2021 to the present, he has been a director of Renhe (Group) Development Co., Ltd. (the company's controlling shareholder), and from February 2023, he has been the vice chairman of Renhe (Group) Development Co., Ltd.
(3) Main contents of the Equity Transfer Agreement
Mr. Yang Wenlong and Mr. Yang Xiao signed the "Equity Transfer Agreement" on June 10, 2026. According to the agreement, Yang Wenlong transferred his equity in Renhe Group with a subscribed capital contribution of RMB 137.5853 million, accounting for 73.1137% of the registered capital of the target company, to Yang Xiao. Both parties confirmed that Yang Xiao does not need to pay any monetary equity transfer price to Yang Wenlong for this transfer of the target equity, and the agreement will take effect from the date of signing.
Changes in actual controller of the company
As of now, the company's controlling shareholder Renhe Group holds 23.24% of the company's shares. This equity change is a change in the equity structure of the controlling shareholder Renhe Group. It does not involve changes in the company's shares held by Renhe Group and will not result in a change in the company's controlling shareholder. After this equity change, the actual controller of the company will be changed from Mr. Yang Wenlong to Mr. Yang Xiao.
The equity control relationship before and after the actual controller change of the company is as follows:
Before the actual controller changes:
Yang Wenlong
73.11%
Yang Xiao Renhe Group
6.53% 23.24%
Renhe Pharmaceutical
After the actual controller changes:
73.11%
Yang Xiao Renhe Group
6.53% 23.24%
Renhe Pharmaceutical
2. The impact of this equity change and actual controller change on the company
This change in equity is a change in the equity structure of the controlling shareholder Renhe Group. It will not cause changes in the controlling shareholder, affect the stability of the company's operations, cause changes in the company's management, and will not affect the company's independence and ability to continue operating.
The information disclosure obligor involved in this change in equity will prepare and disclose a report on relevant changes in equity in accordance with the "Measures for the Administration of Acquisitions of Listed Companies" and the "Shenzhen Stock Exchange Stock Listing Rules" and other laws and regulations.
The industrial and commercial change registration procedures for this change in the controlling shareholder’s equity structure have not yet been completed. The company will continue to pay attention to the relevant progress of this equity change and perform its information disclosure obligations in a timely manner. Investors are kindly requested to pay attention to investment risks.
3. Documents for reference
"Equity Transfer Agreement"
"Notification Letter Regarding Changes in Equity Structure"
Announcement hereby
Renhe Pharmaceutical Co., Ltd. Board of Directors
June 11, 2026